Telehealth's bet on cheap off-brand weight loss drugs is putting pressure on Big Pharma to lower pricesByBruce GilPublishedAugust 29, 2024
Eli Lilly's cheaper Zepbound could threaten weight loss business for Hims & HersByBruce GilPublishedAugust 28, 2024
How will years of weight loss drugs affect changing teen bodies? Novo Nordisk wants to find outByBruce GilUpdatedAugust 27, 2024
Eli Lilly just cut some Zepbound prices in half — but there's a catchByBruce GilPublishedAugust 27, 2024
An Ozempic rival is 'onto something pretty amazing' with experimental weight loss drugs, investor saysByBruce GilPublishedAugust 26, 2024
A digital health care company is selling off-brand Wegovy in a new $250 weight loss programByBruce GilPublishedAugust 21, 2024
Ozempic may be linked to a higher rate of suicidal thoughts, new study saysByBruce GilPublishedAugust 20, 2024
Eli Lilly's weight loss drug almost eliminates the risk of diabetes in overweight adultsByBruce GilPublishedAugust 20, 2024
Pfizer is betting on next-gen cancer drugs to offset slowing demand for COVID vaccinesByBruce GilPublishedAugust 19, 2024
The FDA just approved a gel that can stop bleeding from gunshot wounds in secondsByBruce GilPublishedAugust 15, 2024
Health stocks are surging after the WHO declared monkeypox a global emergencyByBruce GilPublishedAugust 15, 2024
Stop selling off-brand weight loss drugs, Eli Lilly warns companiesByBruce GilPublishedAugust 14, 2024
FDA approves nasal spray alternative to EpiPens for allergic reactionsByBruce GilPublishedAugust 12, 2024
